Cargando…

Efficacy and Safety of Insulin Degludec for Hyperglycemia Management in Noncritical Hospitalized Patients with Diabetes: An Observational Study

INTRODUCTION: To assess the efficacy and safety of insulin degludec administered in a basal-bolus regimen according to the GesTIO protocol in noncritical hospitalized patients with T1DM and T2DM. METHODS: Mean blood glucose levels (BG) and their standard deviations (SD) at admission vs. discharge we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simioni, Natalino, Filippi, Alessio, Scardapane, Marco, Nicolucci, Antonio, Rossi, Maria Chiara, Frison, Vera
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544608/ https://www.ncbi.nlm.nih.gov/pubmed/28585180 http://dx.doi.org/10.1007/s13300-017-0271-6

Ejemplares similares

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
por: Kalra, Sanjay
Publicado: (2016)

Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients
por: Mendez, Carlos E., et al.
Publicado: (2014)

Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patients
por: Gonzalez-Gonzalez, Jose Gerardo, et al.
Publicado: (2013)

Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec–Liraglutide (Ideglira)
por: Zenari, Luciano, et al.
Publicado: (2020)

Real-world Accuracy of CGM in Inpatient Critical and Noncritical Care Settings at a Safety-Net Hospital
por: Finn, Erin, et al.
Publicado: (2023)

Impact of Insulin Degludec in Type 2 Diabetes: Real-World Data on Effectiveness and Safety
por: Ponzani, Paola, et al.
Publicado: (2018)

Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
por: Thuillier, Philippe, et al.
Publicado: (2015)

Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data
por: Kaku, Kohei, et al.
Publicado: (2017)

Patient safety and minimizing risk with insulin administration – role of insulin degludec
por: Aye, Myint M, et al.
Publicado: (2014)

Comparative Effectiveness of Switching From First-Generation Basal Insulin to Glargine 300 U/ml or Degludec 100 U/ml in Type 1 Diabetes: The RESTORE-1 Study
por: Laviola, Luigi, et al.
Publicado: (2020)

Switching Patients with Type 1 Diabetes to Insulin Degludec from Other Basal Insulins: Real-World Data of Effectiveness and Safety
por: Ponzani, Paola, et al.
Publicado: (2019)

Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
por: Moon, Shinje, et al.
Publicado: (2021)

Comparative effectiveness and safety of glargine 300 U/mL versus degludec 100 U/mL in insulin-naïve patients with type 2 diabetes. A multicenter retrospective real-world study (RESTORE-2 NAIVE STUDY)
por: Fadini, Gian Paolo, et al.
Publicado: (2022)

Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100
por: Alexopoulos, Anastasia‐Stefania, et al.
Publicado: (2021)

Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011)

Efficacy and Safety of Insulin Degludec versus Insulin Glargine: A Systematic Review and Meta-Analysis of Fifteen Clinical Trials
por: Liu, Wei, et al.
Publicado: (2018)

Efficacy and Safety of Insulin Degludec/Insulin Aspart (IDegAsp) in Type 2 Diabetes: Systematic Review and Meta-Analysis
por: Edina, Brenda C, et al.
Publicado: (2022)

Efficacy and safety of therapeutic vs. prophylactic bemiparin in noncritically ill patients with COVID-19 pneumonia
por: Varona, Jose F, et al.
Publicado: (2022)

In-hospital experience with insulin degludec (IDeg)
por: Bulisani, Maria Gabriela Pedigoni, et al.
Publicado: (2015)

Pediatric diabetes: Potential for insulin degludec
por: Kalra, Sanjay, et al.
Publicado: (2014)

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
por: Liu, Hongzhong, et al.
Publicado: (2021)

Real-world efficacy and safety of insulin degludec with mealtime rapid-acting insulin in type 1 diabetes in Indian pediatric population
por: Kochar, Inderpal Singh, et al.
Publicado: (2018)

Fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin
por: Vilsbøll, Tina, et al.
Publicado: (2019)

Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment
por: Kiss, István, et al.
Publicado: (2013)

Degludec: the new ultra-long insulin analogue
por: Tambascia, Marcos Antonio, et al.
Publicado: (2015)

A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study)
por: Shimoda, Seiya, et al.
Publicado: (2016)

Safety and Clinical Outcomes of Insulin Degludec in Korean Patients with Diabetes in Real-World Practices: A Prospective, Observational Study
por: Lee, Byung Wan, et al.
Publicado: (2023)

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
por: Kalra, Sanjay
Publicado: (2014)

Reduced Rates of Hypoglycemia in Type 1 or Type 2 Diabetes After Switching to Insulin Degludec: Results from the Italian Cohort of the ReFLeCT Study
por: Fadini, Gian Paolo, et al.
Publicado: (2020)

Insulin/carbohydrates ratio during the first 6‐month therapy with insulin degludec in a paediatric population with type 1 diabetes previously treated with insulin glargine. An observational longitudinal study
por: Tumini, Stefano, et al.
Publicado: (2020)

Evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring
por: Takeishi, Soichi, et al.
Publicado: (2015)

Comparison of the efficacy and safety of insulin degludec/aspart (twice‐daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy)
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Efficacy and safety of insulin degludec in Japanese patients with type 1 and type 2 diabetes: 24‐week results from the observational study in routine clinical practice
por: Kobuke, Kazuhiro, et al.
Publicado: (2015)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
por: Kalra, Sanjay
Publicado: (2013)

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment
por: Kupčová, Viera, et al.
Publicado: (2013)

SUN-179 Prolonged Hypoglycemia from Insulin Degludec
por: Kothari, Vallari, et al.
Publicado: (2019)

Persistent Hypoglycemia Induced by Long-acting Insulin Degludec
por: Katakura, Yukino, et al.
Publicado: (2021)

Long-Term Safety and Clinical Outcomes with Insulin Degludec/Insulin Aspart Treatment in Japanese Patients with Diabetes: A Real-World, Prospective, Observational Study
por: Katabami, Takuyuki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_seejn0cstq01ntc3l2dkin4gf6